Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102 plus pembrolizumab with or without chemotherapy in first-line metastatic non-small cell lung cancer
NL-OMON46066Phase 2Active, not recruiting
- Sponsor
- IO Biotech
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of io102 and pembrolizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (4 cohorts), sponsored by IO Biotech. Primary endpoints: Phase I safety and tolerability and Objective response rate. Started Sep 2018; status: active, not recruiting.
02
Drugs
io102pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON46066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46066.